Skip to navigation Skip to content



About this Medication
  • Brand Name: Briumvi™ (bree-um’-vee)
  • Chemical Name: ublituximab-xiiy
  • Usage in MS: Disease-Modifying Agent
  • Generic Available: No

This medication is taken by intravenous (IV) infusion.


Briumvi is a monoclonal antibody that binds to a molecule (CD20) on the surface of immune cells called B cells and depletes (removes) them from circulating in the blood. B cells have several functions including making antibodies, and evidence suggests they play a role in the damage to the brain and spinal cord in MS.

Briumvi is approved by the FDA for the treatment relapsing forms of multiple sclerosis in adults, which include clinically isolated syndrome, relapsing-remitting MS and active secondary progressive MS.

Click to read the Prescribing Information for healthcare professionals.
Click to read the Medication Guide for patients.


Briumvi Patient Support

Financial Assistance Program

Briumvi Patient Support


© 2023 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.